MAN2B1

Across TCGA pan-cancer cohorts, MAN2B1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAN2B1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAN2B1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAN2B1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where MAN2B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	1.000	0.364	.002	12	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	10	view →
LSCC	OS	Median	All	0.949	0.822	.007	6	view →
OV	DFS	Tertile	All	0.490	0.845	.034	4	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →
GBM	OS	Median	All	0.792	0.915	.022	2	view →
PDAC	OS	Median	All	0.514	0.333	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAN2B1–LUAD (OS)

Open the LUAD breakdown →